Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn's disease: results from a multicentre cohort study.

Péter Bacsur,Mária Matuz,Tamás Resál,Pál Miheller,Tamás Szamosi,Eszter Schäfer,Patrícia Sarlós,Ákos Iliás,Kata Szántó,Mariann Rutka,Anita Bálint,Ágnes Milassin,Anna Fábián,Renáta Bor,Zoltán Szepes,Tamás Molnár,Klaudia Farkas

Therapeutic advances in gastroenterology（2022）

引用 0|浏览9

暂无评分

摘要

VDZ and UST were safe and effective for treating patients with CD in whom anti-TNF therapy failed. UST showed superior drug persistence than VDZ, but dose escalation was more frequent. Biologicals used in lower treatment lines resulted in better drug persistence.

查看译文

关键词

drug persistence,predictors,superiority,ustekinumab,vedolizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要